CUV 1.61% $14.68 clinuvel pharmaceuticals limited

Ann: Media release - First stroke patient with afamelanotide, page-16

  1. 594 Posts.
    lightbulb Created with Sketch. 281
    Are those quoted success figures for drugs that are already approved translating into new indications or new unapproved drugs? I know the answer just thought you might want to correct your post so you can't be accused of trying to mislead. So, there is risk and time involved in bring a drug to market for a new indication. Who knew? Amazing insight. The issue Clinuvel shareholders have is the chance of success is not priced in and it is frustrating compared to our peers.
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.